News

WuXi News

Filter By

2015/08/14

Wuxi Pharmatech Enters Into Definitive Merger Agreement

WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.

Read more

2015/08/10

WuXi PharmaTech and TruTag Technologies Complete Successful Testing of Edible On-Dose Authentication Solution for Pharmaceuticals

SHANGHAI and HONOLULU, August 10, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and TruTag Technologies, Inc., developer of an innovative edible security platform for pharmaceuticals, today announced the successful completion of joint testing of TruTag's on-dose authentication solution.

Read more

2015/05/22

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

SHANGHAI, May 22, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

Read more

2015/05/21

WuXi Launches e-Commerce Platform for Chemistry Products

SHANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemistry R&D, sourcing, and quality control, LabNetwork will bring trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide.

Read more

2015/04/23

WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release

WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the first quarter of 2015 after the New York Stock Exchange closes on Wednesday, May 13, 2015 (which will be Thursday morning, May 14, 2015 Shanghai time).

Read more